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Introduction
Migraine is a common and complex disease, with 
an estimated prevalence of about 10–15% of the 
population worldwide [Smitherman et al. 2013]. 
It is characterized by recurrent headache pain that 
can be accompanied by several autonomic symp-
toms, such as nausea, vomiting, and sensitivity to 
light (photophobia) and sound (phonophobia) 
[Burstein et  al. 2015]. Migraine can be exacer-
bated by a number of triggers, such as physical 
activity, specific kinds of food or alcohol intake, 
hormonal changes and stress [Sauro and Becker, 
2009; Hoffmann and Recober, 2013]. Moreover, 
in about one-third of cases, headache attacks 
might be preceded by the aura, comprising fully 
reversible sensory, visual or dysphasic symptoms 
[International Headache Society, 2013]. Migraine 
has a high impact on patients’ quality of life, caus-
ing both short- and long-term disability, lowering 
work productivity and affecting social relation-
ships and family life [Baigi and Stewart, 2015]; 
therefore efforts should be made to find an 
appropriately effective treatment for each patient. 
In fact, a large number of medications are availa-
ble for both acute and preventive migraine treat-
ment that should be individualized and tailored 
to the patient’s clinical features [Becker, 2015]. 
Triptans represent the first-line abortive treatment 
for moderate-to-severe migraine attacks and mild-
to-moderate attacks that failed to respond to anal-
gesics and anti-inflammatory drugs [Gilmore and 
Michael, 2011]. The triptan family consists of 
seven molecules (sumatriptan, zolmitriptan, elet-
riptan, naratriptan, rizatriptan, almotriptan, fro-
vatriptan) that, despite the biochemical similarity, 
show a definite and distinctive pharmacokinetic 
and pharmacodynamic profile [Jhee et al. 2001]. 
Because of their longer half-lives, naratriptan and 
frovatriptan have a delayed onset of action with a 
more prolonged duration compared with the other 
fast-acting triptans, that display a rapid dose-
dependent efficacy with a higher risk of adverse 
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effects and migraine recurrence [Markus and 
Mikko, 2007; Negro et al. 2011]
Triptan selection for each patient is a complex 
process that should take into account several vari-
ables: the characteristics of migraine attacks 
(speed of onset, intensity of pain, duration of the 
attack), the drug onset of action, the individual 
patient response and tolerance, the relief of asso-
ciated symptoms, the headache recurrence, the 
consistency of the response, the different delivery 
systems and the patient characteristics (medical 
history, lifestyle and working habits) [Belvìs et al. 
2009]. Although the choice of a specific treat-
ment is based mainly on the drug efficacy and 
safety profile, and therefore on its pharmacoki-
netic and pharmacodynamic properties [Géraud 
et  al. 2003], recently, the role of inherited and 
acquired genetic variations in drug response has 
also been highlighted [Gentile et al. 2011; Negro 
et  al. 2011]. As shown in Table 1, eletriptan 
shows the most complex pharmacokinetic/
dynamic profiles among triptans and therefore a 
possible higher chance of bio and drug interac-
tions (see http://www.drugbank.ca/). In this 
review, we will discuss with a systematic approach 
the eletriptan pharmacodynamic and pharma-
cokinetic features, considering the emerging data 
on its clinical efficacy, safety and tolerability pro-
file in the treatment of migraine [Mathew et  al. 
2003a]. We searched the Medline/PubMed and 
EMBASE databases for citations of studies 
reported in English with no time limits. Additional 
citations were identified in the bibliographies of 
published reports. The terms used as search key-
words were ‘eletriptan’ and ‘pharmacokinetics’, 
‘pharmacodynamics’, ‘interactions’, ‘clinical effi-
cacy’, ‘safety’, ‘side effects’, ‘comparative trial’. 
Abstracts of reports, so identified, were inspected 
independently by three reviewers with research 
experience in the clinical study of eletriptan. 
Reports included for detailed review and analysis 
were required to link eletriptan treatment with 
significant clinical efficacy, safety, tolerability and 
drug interactions data. We did not include all 
nonclinical studies.
Eletriptan biochemical and pharmacological 
features
Eletriptan is a relatively new drug, approved by 
the US Food and Drug Administration (FDA) on 
Table 1. Triptan’s pharmacodynamic and pharmacokinetic features.
Sumatriptan Eletriptan Zolmitriptan Almotriptan Naratriptan Rizatriptan Frovatriptan
Targets 5-HT1D
5-HT1B
5-HT1F
5-HT1A
5-HT1D
5-HT1B
5-HT1F
5-HT1A
5-HT1E
5-HT2B
5-HT7
5-HT1D
5-HT1B
5-HT1F
5-HT1A
5-HT1D
5-HT1B
5-HT1D
5-HT1B
5-HT1F
5-HT1A
5-HT1D
5-HT1B
5-HT1F
5-HT1D
5-HT1B
Enzymes MAO-A [S] CYP3A4 
[S,Inh]
CYP2D6 [S]
CYP2C9 [S]
CYP2C19 [S]
PTGS1 [S]
CYP2A6 [Ind]
CYP1A2 [S]
MAO-A [S]
CYP3A4 [S]
CYP2D6 [S]
CYP1A2 [S]
CYP2C19 [S]
CYP2E1 [S]
CYP2C8 [S]
MAO-A [S]
FMO3 [S]
MAO-A [S] MAO-A [S]
CYP1A2 [S]
CYP1A2 [S]
Transporters SLCO1A2 [Ind]
MRP1 [Inh]
ABCG2 [S]
SLCO1B1 [S]
MRP1 [S] – – – – –
Half-life 2.5 hours 4 hours 3 hours 3–4 hours 5–8 hours 2–3 hours 26 hours
Bioavailability 15% 50% 40% 70% 74% 45% 20–30%
Protein binding 14–21% 85% 25% 35% 28–31% 14% 15%
5-HT, 5-hydroxytryptamine; MAO-A, monoaminooxigenase-A; CYP, cytocrome P450; PTGS, prostaglandines G/H synthase; FMO, dimethylaniline 
monooxygenase [N-oxide-forming]; SLCO, solute carrier organic anion transporter; MRP, multidrug-resistant protein; ABCG, ATP-binding  
cassette subfamily G; [S], substrate; [Ind], inducer; [Inh], inhibitor. Pharmacokinetic data for sumatriptan are related to the oral formulation.
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26 December 2002, for the acute treatment of 
migraine with or without aura in adults. Eletriptan 
is a methylpyrrolidinyltryptamine substituted 
with a benzene sulfonyl derivative and belongs to 
the class of organic compounds known as indoles 
(Figure 1). Its chemical name is (R)-3-(1-methyl-
2-pyrrolidinylmethyl)-5-(2-phenylsulphonyl)
ethyl-1H-indole and it has a molecular weight of 
382.52 Daltons.
It shows a rapid and consistent absorption, high 
oral bioavailability and a potent activity as a 
5-hydroxytryptamine 1-receptor subtype B/D 
(5-HT1B/1D)-receptor agonist [Sandrini et  al. 
2009]. It has a proven efficacy profile for the 
acute treatment of moderate-to-severe migraine 
headache attacks, with a high safety and tolerabil-
ity profile regardless of age and sex, for both 
short- and long-term treatment [Mathew et  al. 
2003a]. Eletriptan is commercially available at 
doses of 40 mg or 80 mg, and has been demon-
strated to be effective nearly 30 minutes after the 
administration. In comparative clinical trials (dis-
cussed below) eletriptan (40 and 80 mg) showed 
superior or equivalent efficacy to other triptans 
with high safety and tolerability [McCormack 
et al. 2006], and the most favorable cost effective-
ness when compared with other drugs in its class 
[Sandrini et al. 2009; Bhambri et al. 2015].
Pharmacodynamics
Marketed triptans, including eletriptan, are char-
acterized by a potent and highly selective affinity 
(pKi = 8–9) for 5-HT1B and 5-HT1D receptors, 
involved in the pathophysiology of migraine 
(Table 1). In fact, 5-HT1B and 5-HT1D activa-
tion has a vasoconstrictive action in painfully 
dilated cerebral blood vessels, an inhibitory 
action on vasoactive neuropeptide release by 
trigeminal nerves and reduces nociceptive neuro-
transmission [Tepper et  al. 2002]. Eletriptan, 
similarly to the other triptans, with the exception 
of frovatriptan and almotriptan, has also agonist 
activity for the human 5-HT1F receptor (Table 1) 
[Jähnichen et  al. 2004]. The functional signifi-
cance of 5-HT1F receptors still remains partly 
unknown, even if their capability to inhibit the 
activation of second-order neurons, and there-
fore the transmission of nociceptive information, 
within the trigeminal nucleus caudalis (TNC) 
has been demonstrated [Shepheard et al. 1999]. 
Moreover, 5-HT1F mRNA has been found in the 
trigeminal ganglion and human cerebral and cor-
onary arteries, suggesting a potential role of these 
receptors in cerebrovascular functions and dural 
inflammation, with a potential involvement in 
migraine pathogenesis [Bouchelet et  al. 1996]. 
Eletriptan affinity with unknown pharmacologi-
cal action has also been demonstrated for 
5-HT1A, 5-HT1E, 5-HT2B, and 5-HT7 [Johnson 
et al. 2001].
Eletriptan has no clinically significant activity at 
any other pharmacologic targets (e.g. 5-HT3, 
5-HT4, 5-HT5A, 5-HT6, α1, α2, or β-adrenoceptors; 
adenosine A1, dopamine D1, or D2, muscarinic, 
histaminic) (Table 1). This lack of affinity at 
other receptors is the pharmacologic basis for the 
high degree of safety and tolerability of the triptan 
class [Mathew et al. 2003a].
The putative mechanisms of eletriptan therapeu-
tic action in migraine are multiple: (i) it has a 
vasoconstrictive action on dilated meningeal 
blood vessels; (ii) in perivascular trigeminal sen-
sory neurons it inhibits the release of vasoactive 
neuropeptides and (iii) reduces the pain signal 
transmission in the trigeminal dorsal horn [Derry 
et al. 2010]. The vasoconstrictive action has been 
demonstrated in vitro for isolated canine and 
human arteries, and the vasoconstriction of iso-
lated human meningeal artery with a potency 
similar to that of sumatriptan (EC50 = 50 nm) has 
been demonstrated. Notably, eletriptan is greatly 
less potent in inducing vasoconstriction of iso-
lated human coronary artery (EC = 4299 nm) 
[Milton et al. 2002]. Therefore, eletriptan is con-
sidered a selective vasoconstrictive drug for the 
intracranial blood vessels compared with the 
other extracranial vessels, and in particular with 
coronary arteries [Diener and McHarg, 2000].
Pharmacokinetics
Eletriptan is orally administered in tablets of 
20 mg and 40 mg, with a maximum daily dose of 
80 mg [Derry et  al. 2010]. The absorption, 
Figure 1. Eletriptan chemical structure.
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central nervous system penetration and volume of 
distribution are higher than those of the other 
triptans, given the greater lipophilicity of elet-
riptan [+0.5 (log D at pH 7.4)] [Sandrini et al. 
2009]. After oral intake, the absorption from the 
gastrointestinal tract is rapid, and the mean time 
to maximum concentration (Tmax) is about 2 
hours during an acute migraine attack. The bioa-
vailability is around the 50%, the maximum plasma 
concentration (Cmax) around 188–234 ng/ml, the 
protein binding approximately 85%, and the half-
life is relatively long (3.6–5.5 hours) [Shah et al. 
2001]. Brain penetration by eletriptan is limited 
by the active P-glycoprotein (P-gp), the blood–
brain–barrier efflux system that removes lipo-
philic drugs from the central nervous system 
[Evans et al. 2003]. In fact, the P-gp efflux pump 
has been demonstrated both to modulate the elet-
riptan oral exposure and to reduce the brain 
exposure by approximately 40-fold, accounting 
for the large administered oral dose.
Pharmacokinetic parameters are linear over the 
clinical-dose range, and are not affected by age, 
sex, race or time in the menstrual cycle. Eletriptan 
clearance is mainly nonrenal, and about 90% is 
eliminated by metabolism (principally hepatic) 
[Belvis et al. 2014]. The cytochrome P-450 sys-
tem is responsible for the hepatic metabolism of 
eletriptan, and primarily from the CYP3A4 
enzyme, with a minor contribution of the other 
CYP enzymes. The only known active metabolite 
of eletriptan, N-desmethyleletriptan, is generated 
during hepatic metabolism and shows a plasma 
concentration of about the 10–20% of the parent 
drug.
Eletriptan may interact with substrates, inhibitors 
and inducers of the CYP3A4 enzyme. In fact, the 
co-administration of eletriptan with other medi-
cations able to modify CYP3A4 function might 
increase or decrease eletriptan plasma levels, with 
increased risk of development of adverse effects 
or reduced clinical efficacy [Takiya et al. 2006]. 
The co-administration of maximum doses of elet-
riptan and ketoconazole, a potent CYP3A4 inhib-
itor, was associated with a 2.7 fold Cmax increase 
and a 6-fold increase in the area under the curve 
(AUC) [Mathew et al. 2003a]. As expected, the 
Cmax and AUC of eletriptan were decreased when 
co-administered with mild or moderate CYP3A4 
inhibitors (fluconazole, erythromycin, and vera-
pamil). Although it is a substrate, eletriptan is not 
able to inhibit or induce any CYP enzyme and 
therefore it has no clinically relevant interactions 
with other medications [Mathew et al. 2003a].
Eletriptan metabolism by the prostaglandin G/H 
synthase 1 (or cyclooxigenase-1) has been also 
reported [Zhou et al. 2009]. Notably, frovatriptan 
and eletriptan are the only triptans not metabo-
lized by monoamino-oxydase 1, thus, have no risk 
of interaction with drugs acting on these enzymes 
(Table 1).
Clinical Efficacy
Triptans
Triptans are considered the first-line option for the 
treatment of moderate-to-severe acute migraine 
and for the mild-to-moderate acute migraine 
attacks with poor response to nonsteroidal anti-
inflammatory drugs (NSAIDs) or combinations 
of other analgesics. Principal contraindications 
to triptan prescription are ischemic cardiac, 
cerebrovascular or peripheral vascular diseases 
and pregnancy [Belvis et al. 2014]. Triptan effi-
cacy in treating acute migraine attacks has been 
proven from the results of about 100 double-
blind, randomized trials. Efficacy has been evalu-
ated mainly through the parameters ‘pain free 
after 2 hours’, ‘headache response’, ‘sustained 
pain-free response’, ‘headache recurrence’ and 
‘rescue-medication use’, even if the complete 
response (headache disappearing after 2 hours, 
with no recurrence in the next 24 hours) is the pre-
ferred effect appreciated by patients [Nett et  al. 
2007]. For this reason, the International Headache 
Society (IHS) suggests that a complete response 
should be the standard parameter by which to 
evaluate drugs for migraine attacks [Belvis et  al. 
2014]. However, key outcomes, such as speed and 
duration of pain relief, improvement in migraine-
associated symptoms and risk of side effects also 
influence patients’ satisfaction.
The seven marketed triptans have shown relief 
with or without absence of pain after 2 hours and a 
decrease of rescue-medication use if patients are 
treated early, when headache begins. Moreover, 
they have shown clinical efficacy in the reduction of 
the migraine-associated symptoms, such as nausea, 
vomiting, photophobia and phonophobia [Bigal 
et al. 2009]. Patients who experience inefficacy with 
single administration might also use an additional 
dose that is effective in about the 15–40% of cases 
[Ferrari et al. 1994; Belvis et al. 2014].
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Eletriptan: efficacy versus placebo
Eletriptan has demonstrated a consistent and sig-
nificant clinical efficacy and a good tolerability 
profile in the treatment of migraine. The clinical 
efficacy of eletriptan at suggested dosages has 
been compared in several trials (head to head and 
placebo) for the treatment of moderate-to-severe 
acute migraine attacks.
In a placebo-controlled trial of one migraine attack 
treated with eletriptan, it was superior against pla-
cebo at all available dosages (20, 40 and 80 mg) 
for headache relief at 2 hours. All the doses were 
superior to the placebo response of 51%, and 20, 
40 and 80 mg sustained a 2-hour headache relief 
of 64%, 67%, and 76%, respectively [Stark et al. 
2002]. Eletriptan 20 and 40 mg were studied ver-
sus placebo in another trial for one migraine-attack 
treatment and showed headache-free rates at 2 
hours, 35% for 20 mg, and 47% for 40 mg, with a 
placebo response of 22% [Brandes et al. 2005]. In 
patients with moderate headache, the 40 mg dose 
showed a 2-hours headache-free rate of 68% com-
pared with the 25% of placebo. Another placebo-
controlled study showed that eletriptan 20, 40 and 
80 mg doses had a 2-hour headache-relief rate of 
47%, 62% and 59%, respectively, compared with 
a placebo response of 22% [Sheftell et al. 2003]. 
In the same study, the pain-free responses at 2 
hours were 14%, 27%, and 27% for the 20, 40 
and 80 mg eletriptan doses, respectively, with a 
placebo headache-free response of 4% [Sheftell 
et  al. 2003]. An additional placebo-controlled 
study of eletriptan doses of 40 and 80 mg showed 
similar rates of headache relief and freedom after 2 
hours (40 mg: 62% headache relief, 32% head-
ache freedom; 80 mg: 65% headache relief, 34% 
headache freedom; placebo: 19% headache relief, 
3% headache freedom) [Stark et  al. 2002]. 
Moreover, the efficacy and tolerability of the three 
doses of eletriptan (versus placebo) were demon-
strated to be similar in triptan-naïve and triptan-
experienced patients, indicating that the previous 
treatment status does not influence eletriptan 
response [Martin et al. 2007]. In a recent multi-
ple-attacks study, eletriptan 40 and 80 mg were 
significantly more effective in achieving a 2-hour 
headache response than placebo (response rate: 
72.5% for eletriptan 40 mg, 70% for eletriptan 80 
mg and about 23% for placebo) with a low 
adverse-event rate for both doses [Almas et  al. 
2014; Marmura et al. 2015]. Compared with all 
the marketed triptans, eletriptan was found to be 
among the most effective in two meta-analytic 
studies of published placebo-controlled trials 
[Bhambri et al. 2015]. In a meta-analysis of 53 tri-
als, rizatriptan 10 mg, eletriptan 80 mg and almo-
triptan 12.5 mg showed the highest probability of 
a significant clinical therapeutical effect [Ferrari 
et al. 2001]. Moreover, the most recent meta-anal-
ysis of 74 trials showed eletriptan 40 mg to have 
superiority for at least one of the two considered 
outcomes (pain-free response at 2 hours, sus-
tained pain-free response at 24 hours, headache 
response at 2 hours, and sustained headache 
response at 24 hours), compared with all the other 
triptans. In particular, eletriptan had the highest 
probability of patients being pain-free both at 2 
hours and at 24 hours [Thorlund et  al. 2014; 
Bhambri et al.2015].
Eletriptan: efficacy in head-to-head studies
A recent systematic review and network meta-
analysis of 133 randomized controlled trials that 
compared triptans with placebo-controlled or 
active migraine treatments showed that triptan 
standard doses provided a headache-free response 
in 42–76% of patients and a sustained headache-
free response in 29–50% of patients with a rescue-
medication-use rate of about 27% [Cameron et al. 
2015]. Considering the outcome headache-free 
response at 2 hours, triptan standard doses 
gave better results than ergot’s (42–76% and 
38% response, respectively) and equal or better 
responses than NSAIDs, aspirin and acetami-
nophen [Cameron et  al. 2015; Diener et  al. 
2002]. Moreover, eletriptan tablets, together with 
sumatriptan subcutaneous injection and riza-
triptan and zolmitriptan, showed the most favorable 
responses among all triptans [Cameron et al. 2015]. 
Compared with zolmitriptan, eletriptan 80 mg, 
but not 40 mg, showed significant superiority 
when considering the 2-hour headache-response 
outcome. Nevertheless, eletriptan 40 mg showed 
a significantly lower recurrence rate and need for 
rescue medication over 24 hours [Steiner et  al. 
2003]. Eletriptan (40 mg) also showed a superior 
clinical efficacy (with the same tolerability profile) 
compared with naratriptan (2.5 mg). In fact, both 
2-hours pain-free response and sustained headache-
free response results were higher and use of rescue 
medications lower in the eletriptan group [Garcia-
Ramos et  al. 2003]. Three comparative studies 
have been performed with sumatriptan (50 or 
100 mg) and eletriptan at different doses (20, 40, 
or 80 mg). The results of these trials consistently 
showed eletriptan’s (40 and 80 mg) clinical 
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efficacy and onset of action to be superior when 
compared with oral sumatriptan 100 mg. Both 
sumatriptan and eletriptan were well tolerated, 
with low incidence of adverse effects [Goadsby 
et al. 2000; Mathew et al. 2003b; Sandrini et al. 
2002]. Moreover, eletriptan (compared with pla-
cebo) has been demonstrated as effective in treat-
ing acute migraine in previous nonresponders, or 
patients not tolerant to sumatriptan [Färkkilä et al. 
2003]. Other triptan-switch studies reported elet-
riptan 40 mg efficacy in migraineurs who did not 
also respond to treatment with rizatriptan and 
NSAIDs [Bhambri et al. 2015].
Poor responders to low doses of eletriptan after 
three consecutive migraine attacks were able to 
achieve a 2-hour response rate of 42.5–60% on 
the next three attacks when the dose of eletriptan 
was increased to 80 mg. Therefore, a dose escala-
tion should be considered as an effective strategy 
in approximately 50% of individuals, even if they 
are nonresponders to three consecutive attacks at 
a lower dose [Landy et al. 2014; Almas et al. 2014].
Tolerability and safety
The varying affinity for 5-HT receptors shown by 
the different triptans might not be relevant to the 
antimigraine efficacy, but might affect their toler-
ability profile. Moreover, pharmacokinetic 
parameters of each drug, such as bioavailability, 
lipophilicity, or metabolism are also relevant for 
safety and tolerability. Some of the most common 
adverse effects of triptan-family drugs include 
sleepiness or fatigue, difficulty in thinking, tachy-
cardia and dizziness [Dodick and Martin, 2004].
Eletriptan has been reported in literature as a safe 
and tolerable drug. The most common adverse 
effects are usually transient and associated with 
the eletriptan central nervous system (CNS) 
activity, such as dose-related somnolence, dizzi-
ness, asthenia, and nausea [Sandrini et al. 2009]. 
With regards to relevant clinical change in chem-
istry and vital parameters, no significant altera-
tions have been reported in patients treated with 
eletriptan [Shah et al. 2002]. A common effect is 
a transient increase in mean systolic and diastolic 
blood pressure after 1 hour from eletriptan 
administration, reflecting the time of its Cmax. It 
has been shown that the increase in diastolic 
blood pressure is related to the eletriptan dose, 
whereas the association of systolic blood-pressure 
rise and dosage appears less strong [Shah et  al. 
2002]. Reported severe adverse events were 
generally uncommon, and almost all related to 
cardiovascular acute diseases (acute myocardial 
infarction, arrhythmias, cerebrovascular events), 
especially in patients suffering from previous car-
diovascular disorders. The occurrence of myocar-
dial infarction attributable to eletriptan overdose in 
a patient without coronary artery disease has been 
recently reported but, to best of our knowledge, it 
is a unique case. Notably, eletriptan has been dem-
onstrated in animals to induce coronary constric-
tion at four times higher dose than sumatriptan 
[Muir et  al. 1999]. Therefore, it represents the 
triptan of choice in patients with cardiovascular 
risk factors, without coronary artery disease. In 
any case, patients should be educated to not to 
exceed the indicated dose and to recognise early 
clinical symptoms of angina [Dias et al. 2014].
Sandrini and colleagues reported that eletriptan 
20 and 40 mg and placebo showed similar 
adverse-events rate (with a slight increase for the 
40 mg), whereas the dose of 80 mg had a higher 
rate compared with the 40 mg dosage (1–7%) 
[Sandrini et al. 2009]. Also, the discontinuation 
rate due to the occurrence of adverse events was 
ranged from 0.2% (40 mg) to 1.6% (80 mg), and 
in other studies is reported as between 2% and 
8% [McCormack et al. 2006; Almas et al. 2014]. 
The adverse-events frequency of eletriptan 20 
and 40 mg is similar to that of supatriptan 50 and 
100 mg, whereas the incidence with eletriptan 
80 mg is slightly higher. Severe and serious 
adverse events are uncommon. The tolerability of 
eletriptan is also stable for long-term treatments 
and the incidence of adverse events may decrease 
over time [McCormack et al. 2006].
Among triptans, frovatriptan, rizatriptan, zolmi-
triptan, and eletriptan exhibit a higher frequency 
of central side effects possibly related to the pres-
ence of their active N-desmethyl metabolites. 
Although no data are available on the contribu-
tion of active metabolites of eletriptan to its toler-
ability profile, the higher lipophilicity of 
N-desmethyl eletriptan might be related to its 
ability to cross the blood–brain barrier. Together 
with the hypothesized higher brain concentration 
than the parent drug, N-desmethyl eletriptan 
might also be able to interact with 5-HT or other 
receptors associated with CNS side effects 
[Dodick and Martin, 2004].
Occurrence of serotonin-syndrome risk, when 
combining treatment with triptans and serotonin-
ergic antidepressants has been reported by the 
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FDA. In a review of seven studies involving a 
large number of patients treated with eletriptan, 
with 306 patients coprescribed with serotoniner-
gic antidepressants, no serious adverse events 
occurred [Tepper et al. 2003; Hettiarachchi and 
Kurrell, 2001]. Moreover, serotoninergic antide-
pressants might rarely precipitate serotonin syn-
drome when prescribed alone [Spigset, 1999]. 
Triptans and selective serotonin reuptake inhibi-
tors (SSRIs) are frequently coprescribed because 
of the high comorbitity of migraine with anxiety 
and depression. The absence of a corresponding 
high number of serotoninergic-syndrome reports 
in the literature suggests that this adverse event is 
likely extremely rare [Tepper et al. 2003].
The FDA have assigned eletriptan to pregnancy 
category C (i.e. despite the absence of controlled 
data in human pregnancy, some previous studies 
carried out in animal models have shown evi-
dence of toxicity with regard to the fetal develop-
ment). Therefore, the prescription of eletriptan in 
pregnant migraineurs should only be considered 
in the absence of further alternatives [US Food 
and Drug Administration, 2013]. Furthermore, 
there is no previous information on increased risk 
of congenital malformations associated to triptan 
treatment during pregnancy, although the use of 
triptans during the second or third trimesters of 
pregnancy has been associated with a mild incre-
mental increase in the risk of atonic uterus and 
hemorrhage [Nezvalová-Henriksen et  al. 2010]. 
However, much lower eletriptan concentrations 
were detected in human breast milk when com-
pared with maternal serum levels and, conse-
quently, it is not likely to induce adverse effects in 
infants [Soldin et al. 2008].
Likewise, considering the eletriptan metabolism 
and the increase of CYP3A4 activity during preg-
nancy, modifications on the eletriptan efficacy 
profile should be also taken into account [Soldin 
et al. 2008].
Bio and drug interactions of clinical significance
The frequent prescription of a multiple-drug-
therapy regimen for migraine, especially in its 
chronic form, increases the risk of occurrence of 
clinically significant drug–drug interactions 
(DDIs). In particular, patients treated chronically 
with the prophylactic therapy usually use triptans 
or other analgesics during an acute attack. The 
wide variety of both preventive and acute drugs 
and their possible pharmacological interactions 
complicates the choice of a combination therapy 
with a low rate of clinically significant DDIs 
[Lionetto et al. 2016].
Metabolism of eletriptan is primarily hepatic, 
with a main role of cytochrome P450 3A4 
(CYP3A4). In patients with mild-to-moderate 
hepatic impairment treated with eletriptan, there 
is an increase in peak plasma concentration (Cmax, 
18%) and in the systemic exposure (AUC, 34%). 
Dosage adjustment in these patients might be not 
necessary. The use of eletriptan in patients with 
severe hepatic impairment has not been studied, 
therefore is not recommended [US Food and 
Drug Administration, 2013].
Given the most exclusive metabolism by CYP3A4, 
the eletriptan coprescription with drugs metabo-
lized by the same cytochrome has been evaluated. 
In EU labeling, drugs contraindicated with elet-
riptan belong to the potent inhibitors of CYP 3A4 
[inhibitory constant (Ki)] in vitro of 25 mol or 
less). Ketoconazole, itraconazole, erythromycin, 
clarithromycin, josamycin, ritonavir, nelfinavir, 
and indinavir are some of the CYP3A4 potent 
inhibitors [Thomas Healthcare, 2001]. Clinically 
significant pharmacokinetic interactions with 
eletriptan have been reported for several of these 
drugs, such as verapamil and fluconazole [Thomas 
Healthcare, 2001; Thummel and Wilkinson, 
1998]. In the US, the intake of eletriptan before 
72 hours from the treatment with a potent 
CYP3A4 inhibitor it is not recommended because 
of the risk of plasma concentration elevation. 
However, the frequency and severity of adverse 
events due to the co-administration of eletriptan 
and CYP3A4 inhibitors did not appear to be 
increased [Sandrini et al. 2009]. In a large study 
of patients treated with triptans, it was reported 
that, probably because of the wide variety of drugs 
metabolized by CYP3A4 [Thummel and 
Wilkinson, 1998], about half of the patients 
treated with triptans also received CYP 
3A4-metabolized coprescriptions. In particular, 
one-fifth of the patients were coprescribed with 
potent CYP3A4 inhibitors and triptans, and 6% 
specifically with eletriptan [Tepper et  al. 2003]. 
Growing clinician awareness of eletriptan means 
that concomitant prescriptions are not recom-
mended, which might be useful in avoiding pos-
sible adverse events resulting from CYP3A4-based 
pharmacokinetic interactions.
No data have been reported about interactions 
causing any effect on the efficacy or undesired 
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effects of eletriptan and migraine prophylactic 
medications (beta-blockers, tricyclic antidepres-
sants, SSRIs, methysergide and flunarizine). In 
clinical studies, administration of propranolol 
increased the exposure of eletriptan (AUC, 33%); 
but the effect is considered not clinically relevant 
since any increase in blood pressure or other 
adverse effects were associated with co-adminis-
tration when compared with administration of 
eletriptan alone [US Food and Drug 
Administration, 2013]. Slight increases in blood 
pressure were observed with the intake of cafergot 
(caffeine and ergotamine) 1 and 2 hours after 
eletriptan, which is predictable considering the 
pharmacodynamics of the two drugs [Diener et al. 
2002]. Therefore, ergot-type or ergotamine-con-
taining medications (dihydroergotamine or meth-
ysergide) should not be administered within 24 
hours after eletriptan dosing and vice versa 
[DrugBank, 2016]. Beta-blockers, tricyclic anti-
depressants, SSRIs, estrogen-based hormone-
replacement therapy, estrogen-containing oral 
contraceptives and calcium-channel blockers 
have no effect on the pharmacokinetic parameters 
of eletriptan, as demonstrated by population 
pharmacokinetic analysis of clinical studies 
[Sandrini et  al. 2009; Mathew et  al. 2003a]. 
Moreover, monoamine oxidase (MAO) does not 
metabolize eletriptan and therefore has no 
expected interaction with MAO inhibitors [US 
Food and Drug Administration, 2013].
Conclusion
Triptan selection for each patient is a complex 
process that should take into account several clin-
ical, pharmacological and individual variables. 
Among the pharmacological properties, eletriptan 
is a selective 5-HT1 vasoconstrictive drug for the 
intracranial blood vessels compared with the 
other extracranial vessels, with a very low vaso-
constrictive action on coronary arteries. 
Pharmacokinetic parameters are linear over the 
clinical-dose range, and eletriptan is primarily 
metabolized by hepatic cytochrome P450, 
accounting for the higher chance of bio and drug 
interactions. Eletriptan’s clinical efficacy has been 
demonstrated in placebo-controlled and head-to-
head studies. It showed the most favorable clini-
cal responses among all triptans, together with 
sumatriptan subcutaneous injection, rizatriptan 
and zolmitriptan. It is a safe and tolerable drug, 
and is considered the triptan of choice in patients 
with cardiovascular risk factors, without coronary 
artery disease. Severe and serious adverse events 
are uncommon and the incidence of adverse 
events may decrease over time. Although there is 
hepatic metabolism by CYP3A4, any clinically 
relevant interaction has been demonstrated with 
the other first- and second-line prophylactic ther-
apies or other acute treatments for migraine, with 
the exception of ergot derivatives and cafergot. 
Coprescription of eletriptan with drugs such as 
potent CYP3A4 inhibitors and other serotoniner-
gic medications should be carefully considered.
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